Maternal omega-3 fatty acid supplementation may decrease the risk of food allergy and IgE-associated eczema during the first year of life in infants with a family history of allergic disease.

, Allergic disease in infants up to 2 yr of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation inpregnancy and lactation, 2011, Pediatric Allergy and Immunology, (22) Pediatr Allergy Immunol. AbstractBackground: We have previously reported a protective effect of maternal omega-3 long chain

SUMMARY A questionnaire study regarding airway morbidity in children and environmental factors was performed in April 1985. The parents of 5301 children, aged 6 months to 16 years, from different rural areas in mid Sweden were sent a validated questionnaire and 4990 (94%) responded. The cumulative prevalence of bronchial hyperreactivity was 9.7% and of allergic asthma 5.2%. Children living near a paper pulp plant more often had symptoms suggesting bronchial hyperreactivity (124 (13.0%), relative risk 1-3) and allergic asthma (68 (7.1%), relative risk 1.3). In children living in a damp house problem bronchial hyperreactivity was found in 76 (19-0%) (relative risk 1*9) and allergic asthma in 35 (8.7%) of the children (relative risk 1-9). Children living in a damp house with parents who smoked had the highest figures: bronchial hyperreactivity was found in 44 (23.5%) (relative risk 2.8) and allergic asthma in 22 (11-6%) (relative risk 2.5). The results indicate that various moderate environmental pollutants may act synergistically to increase bronchial hyperreactivity and allergy especially in children with a family history of allergy.

The immunological composition of breast milk differs between mothers. The reasons for these differences and the consequences for the breast-fed infants are poorly understood. The aim of this study was to evaluate the effect of probiotic Lactobacillus reuteri supplementation on the immunological composition of breast milk in relation to sensitization and eczema in the babies. Total IgA, secretory IgA (SIgA), TGF-beta1, TGF-beta2, IL-10, TNF, soluble CD14 (sCD14), and Na/K ratios were analyzed in colostrum and mature milk obtained from women treated with L. reuteri (n = 54) or placebo (n = 55) from gestational week 36 until delivery. Bacteriological analyses of L. reuteri were performed in faecal samples of the mothers. The infants were followed prospectively for 2 yr regarding development of eczema and sensitization as defined by a positive skin prick test and/or circulating allergen-specific IgE antibodies at 6, 12, and 24 months of age. Supplementation of L. reuteri during pregnancy was associated with low levels of TGF-beta2 and slightly increased levels of IL-10 in colostrum. For TGF-beta2, this association was most pronounced in mothers with detectable L. reuteri in faeces. Infants receiving breast milk with low levels of TGF-beta2 were less likely to become sensitized during their first 2 yr of life. A similar trend was observed for development of IgE-associated eczema. The levels of total IgA, SIgA, TGF-beta1, TNF, sCD14, and Na/K ratios in breast milk were not affected by the intake of L. reuteri. None of these parameters correlated with sensitization or development of eczema in the infant, except for high Na/K ratios that associated with increased risk of sensitization. Supplementation with L. reuteri during late pregnancy reduces breast milk levels of TGF-beta2, and low levels of this cytokine are associated with less sensitization and possibly less IgE-associated eczema in breast-fed infants.

We found a reduction in all-cause mortality after rectal but not colon cancer in patients having EDA compared with PCA technique.